Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
J01CR02 AYECLAV-T G Amoxicillin - 875mg, Clavulanic Acid - 125mg Tablet 338,648 L.L
C10AA05 ATORVASTATINE ARROW GENERQUES G Atorvastatin - 40mg 40mg Tablet, coated 564,414 L.L
C09CA03 ANGINET G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C09CA03 ARBITEN 160 G Valsartan - 160mg 160mg Tablet 544,256 L.L
D07XC04 AZONIT - D G Diflucortolone valerate - 1mg/g, Isoconazole nitrate - 10mg/g Cream 225,766 L.L
L01EB01 APO-GEFITINIB G Gefitinib - 250mg 250mg Tablet 87,345,820 L.L
L02BG03 ANASTROZOL GP PHARM G Anastrozole - 1mg 1mg Tablet, film coated 1,181,238 L.L
L02BG03 ANASTROZOLE ARROW LAB G Anastrozole - 1mg 1mg Tablet 1,552,138 L.L
J01CR02 AMOCLAN BID G Amoxicillin (trihydrate) - 400mg/5ml, Clavulanic Acid (potassium) - 57.1mg/5ml 457mg/57mg Tablet, chewable 892,311 L.L
L02BG03 ANASTROZOLE BIOGARAN G Anastrozole - 1mg 1mg Tablet, coated 3,800,387 L.L
N05BA08 ANXYL G Bromazepam - 3mg 3mg Tablet, scored 167,660 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 100mg 100mg Tablet 79,672,726 L.L
L02BG03 APO-ANASTROZOLE G Anastrozole - 1mg 1mg Tablet 2,615,118 L.L
D10AD01 A-RET G Tretinoin - 0.05% 0.05% Cream 335,961 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 150mg 150mg Tablet 91,523,229 L.L
N05BA12 ALPRAZOLAM BIOGARAN G Alprazolam - 0.5mg 0.5mg Tablet, scored 169,324 L.L
D10AD01 AVOTIN-A G Tretinoin - 0.05% 0.05% Cream 440,780 L.L
L02BG04 APO-LETROZOLE G Letrozole - 2.5mg 2.5mg Tablet 1,962,010 L.L
N05BA12 ALPROX G Alprazolam - 0.5mg 0.5mg Tablet 383,955 L.L
C09CA04 ANDARAN G Irbesartan - 150mg 150mg Tablet, film coated 940,435 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 80mg 80mg Tablet, coated 564,414 L.L
C10AA05 ATORVASTATINE ARROW GENERIQUES G Atorvastatin - 80mg 80mg Tablet, coated 564,414 L.L
M01AB15 ALGIKEY G Ketorolac trometamine - 30mg/ml 30mg/ml Injectable solution 873,498 L.L
G04BE08 APO-TADALAFIL G Tadalafil - 5mg 5mg Tablet 1,635,456 L.L
N05BA12 ALPRAZOLAM BIOGARAN G Alprazolam - 0.25mg 0.25mg Tablet, scored 115,570 L.L
N05BA12 ALPROX G Alprazolam - 1mg 1mg Tablet 895,895 L.L
C10AA07 APO-ROSUVASTATIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 670,577 L.L
P02CA03 ALBENDA G Albendazole - 100mg/5ml 400mg/20ml Suspension 129,009 L.L
M01AB16 ACECLOFAR G Aceclofenac - 100mg 100mg Tablet 131,697 L.L
P02CA03 ALBENDA G Albendazole - 200mg 200mg Tablet 116,914 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025